Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program

BACKGROUND: Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/ glucagon-like peptide-1 receptor agonist, is approved in the United States, Europe and Japan for the treatment of type 2 diabetes. Across the SURPASS-1 to -5 clinical studies, tirzepatide 5, 10 and 15 mg demonstrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Lingvay, Ildiko, Mosenzon, Ofri, Brown, Katelyn, Cui, Xuewei, O’Neill, Ciara, Fernández Landó, Laura, Patel, Hiren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039543/
https://www.ncbi.nlm.nih.gov/pubmed/36964557
http://dx.doi.org/10.1186/s12933-023-01797-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039543/
https://www.ncbi.nlm.nih.gov/pubmed/36964557
http://dx.doi.org/10.1186/s12933-023-01797-5

Ejemplares similares